NASDAQ: CYTH - Cyclo Therapeutics, Inc.

Rentabilité sur six mois: -8.19%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions Cyclo Therapeutics, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Cyclo Therapeutics, Inc.

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of neurodegenerative diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo that is in Phase IIb clinical trials for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.

plus de détails
The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2011-02-23
ISIN US23254X2018
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://cyclotherapeutics.com
Цена ао 0.7206
Changement de prix par jour: 0% (0.7206)
Changement de prix par semaine: 0% (0.7206)
Changement de prix par mois: +9.02% (0.661)
Changement de prix sur 3 mois: -3.92% (0.75)
Changement de prix sur six mois: -8.19% (0.7849)
Changement de prix par an: -40.45% (1.21)
Evolution du prix sur 3 ans: -75.32% (2.92)
Evolution du prix sur 5 ans: +454.31% (0.13)
Evolution des prix depuis le début de l'année: +19.7% (0.602)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 9.13 1
P/BV 2.06 7
P/E 0 0
EV/EBITDA -0.0803 0
Total: 4.75

Efficacité

Nom Signification Grade
ROA, % -151.4 0
ROE, % -421.64 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.0516 10
Total: 9.4

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 19.2 3
Rentabilité Ebitda, % 122.56 10
Rentabilité EPS, % -77.99 0
Total: 6.4
Plus de détails

Établissements Volume Partager, %
Founders Fund V Management, LLC 480708 1.67
Vanguard Group Inc 355223 1.24
Geode Capital Management, LLC 152077 0.53
Founders Fund VI Management, LLC 110023 0.38
Citadel Advisors Llc 54018 0.19
Blackrock Inc. 48444 0.17
State Street Corporation 39525 0.14
Wealth Enhancement Advisory Services, LLC 18513 0.06
Northern Trust Corporation 17453 0.06
XTX Topco Ltd 10696 0.04



Superviseur Titre d'emploi Paiement Année de naissance
Mr. N. Scott Fine CEO & Director 569.92k 1957 (68 années)
Mr. C. E Strattan Founder & Director N/A 1946 (79 années)
Mr. Joshua M. Fine CFO & Secretary 421.17k 1982 (43 année)
Mr. Michael Eric Lisjak Senior VP of Business Development & Chief Regulatory Officer 430.4k 1974 (51 année)
Dr. Jeffrey L. Tate Ph.D. COO, Chief Quality Officer & Director 255.14k 1958 (67 années)
Dr. Karen Mullen FFPM Interim Chief Medical Officer N/A
Ms. Lori McKenna Global Head of Patient Advocacy N/A

Adresse: United States, Gainesville. FL, 6714 NW 16th Street - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://cyclotherapeutics.com